Andreia Gonçalves

Andreia Gonçalves

Auto-generated profile, based on publicly available information

Andreia Gonçalves

Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Harbor, Michigan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CMCatarina Marques
Catarina Marques
CMCristina Mega
Cristina Mega
AGAndreia Gonçalves
Andreia Gonçalves
Paulo Rodrigues-SantosPaulo Rodrigues-Santos
Paulo Rodrigues-Santos
Edite Teixeira-LemosEdite Teixeira-Lemos
Edite Teixeira-Lemos
Rosa FernandesRosa Fernandes
Rosa Fernandes
This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of type 2 diabetes mellitus; the Zucker diabetic fatty (ZDF) rat: 20-week-old rats were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia and bloodHbA1clevels were monitored, as well as kidney function and lesions. Kidney mRNA and/or protein content/distribution of DPP-IV, GLP-1, GLP-1R, TNF-α, IL-1β, BAX, Bcl-2, and Bid were evaluated by RT-PCR and/or western blotting/immunohistochemistry. Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia andHbA1c(by about 22.5% and 1.2%, resp.) and ameliorated tubulointerstitial and glomerular lesions. Sitagliptin prevented the diabetes-induced increase in DPP-IV levels and the decrease in GLP-1 levels in kidney. Sitagliptin increased colocalization of GLP-1 and GLP-1R in the diabetic kidney. Sitagliptin also decreased IL-1βand TNF-αlevels, as well as, prevented the increase of BAX/Bcl-2 ratio, Bid protein levels, and TUNEL-positive cells which indicates protective effects against inflammation and proapoptotic state in the kidney of diabetic rats, respectively. In conclusion, sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and antiapoptotic properties.

8 December 2011 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
AGA. Gonçalves
A. Gonçalves
ELErmelindo Carreira Leal
Ermelindo Carreira Leal
APArtur Paiva
Artur Paiva
Edite Teixeira-LemosEdite Teixeira-Lemos
Edite Teixeira-Lemos
FTF. Teixeira
F. Teixeira
Rosa FernandesRosa Fernandes
Rosa Fernandes

1 July 2013 in Tissue Barriers
Verified
Journal Article
Open access
AGAndreia Gonçalves
Andreia Gonçalves
António Francisco AmbrósioAntónio Francisco Ambrósio
António Francisco Ambrósio
Rosa FernandesRosa Fernandes
Rosa Fernandes
Claudins are pivotal building blocks of tight junctions that form the paracellular barrier in epithelia and endothelia. In mammals, claudins are a 27-gene family that encodes tetraspan membrane proteins, playing a crucial role in the formation and integrity of tight junctions and regulate the barrier function. Claudin isoforms are expressed in a tissue- and/or developmental stage-dependent manner. A growing body of evidence indicates that pathological states characterized by neuroinflammation, such as Alzheimer disease, multiple sclerosis, diabetic retinopathy and retinopathy of prematurity share a common feature: the barrier breakdown. This review aims integrating and summarizing the most relevant and recent work developed in the field of claudins, with particular attention to their role in blood-brain and blood-retinal barriers, as well as describing their regulation in the aforementioned human diseases.

1 September 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
AGAndreia Gonçalves
Andreia Gonçalves
CMCatarina Marques
Catarina Marques
ELErmelindo Carreira Leal
Ermelindo Carreira Leal
CRCarlos F. Ribeiro
Carlos F. Ribeiro
Flávio ReisFlávio Reis
Flávio Reis
Rosa FernandesRosa Fernandes
Rosa Fernandes

1 May 2016 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
AGAndreia Gonçalves
Andreia Gonçalves
CLCheng-Mao Lin
Cheng-Mao Lin
AMArivalagan Muthusamy
Arivalagan Muthusamy
CRCarlos Fontes Ribeiro
Carlos Fontes Ribeiro
António Francisco AmbrósioAntónio Francisco Ambrósio
António Francisco Ambrósio
DADavid Antonetti
David Antonetti
Purpose: Inflammation associated with blood–retinal barrier (BRB) breakdown is a common feature of several retinal diseases. Therefore, the development of novel nonsteroidal anti-inflammatory approaches may provide important therapeutic options. Previous studies demonstrated that inhibition of dipeptidyl peptidase-IV, the enzyme responsible for the degradation of glucagon-like peptide-1 (GLP-1), led to insulin-independent prevention of diabetes-induced increases in BRB permeability, suggesting that incretin-based drugs may have beneficial pleiotropic effects in the retina. In the current study, the barrier protective and anti-inflammatory properties of exendin-4 (Ex-4), an analog of GLP-1, after ischemia-reperfusion (IR) injury were examined. Methods: Ischemia-reperfusion injury was induced in rat retinas by increasing the intraocular pressure for 45 minutes followed by 48 hours of reperfusion. Rats were treated with Ex-4 prior to and following IR. Blood–retinal barrier permeability was assessed by Evans blue dye leakage. Retinal inflammatory gene expression and leukocytic infiltration were measured by qRT-PCR and immunofluorescence, respectively. A microglial cell line was used to determine the effects of Ex-4 on lipopolysaccharide (LPS)-induced inflammatory response. Results: Exendin-4 dramatically reduced the BRB permeability induced by IR injury, which was associated with suppression of inflammatory gene expression. Moreover, in vitro studies showed that Ex-4 also reduced the inflammatory response to LPS and inhibited NF-κB activation. Conclusions: The present work suggests that Ex-4 can prevent IR injury–induced BRB breakdown and inflammation through inhibition of inflammatory cytokine production by activated microglia and may provide a novel option for therapeutic intervention in diseases involving retinal inflammation.

1 January 2020 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Open access
HRHéloïse Ragelle
Héloïse Ragelle
AGAndreia Goncalves
Andreia Goncalves
SKStefan Kustermann
Stefan Kustermann
DADavid Antonetti
David Antonetti
AJAshwath Jayagopal
Ashwath Jayagopal
The blood–retinal barrier (BRB) protects the retina by maintaining an adequate microenvironment for neuronal function. Alterations of the junctional complex of the BRB and consequent BRB breakdown in disease contribute to a loss of neuronal signaling and vision loss. As new therapeutics are being developed to prevent or restore barrier function, it is critical to implement physiologically relevant in vitro models that recapitulate the important features of barrier biology to improve disease modeling, target validation, and toxicity assessment. New directions in organ-on-a-chip technology are enabling more sophisticated 3-dimensional models with flow, multicellularity, and control over microenvironmental properties. By capturing additional biological complexity, organs-on-chip can help approach actual tissue organization and function and offer additional tools to model and study disease compared with traditional 2-dimensional cell culture. This review describes the current state of barrier biology and barrier function in ocular diseases, describes recent advances in organ-on-a-chip design for modeling the BRB, and discusses the potential of such models for ophthalmic drug discovery and development.